Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VCNX - Vaccinex Inc


IEX Last Trade
5.59
0.060   1.073%

Share volume: 5,271
Last Updated: Fri 30 Aug 2024 04:46:02 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.53
0.06
1.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
40%
Profitability 50%
Dept financing 36%
Liquidity 19%
Performance 35%
Company vs Stock growth
vs
Performance
5 Days
6.51%
1 Month
-28.91%
3 Months
10.19%
6 Months
-34.59%
1 Year
-87.25%
2 Year
-97.00%
Key data
Stock price
$5.59
P/E Ratio 
-0.56
DAY RANGE
N/A - N/A
EPS 
-$1.57
52 WEEK RANGE
$4.21 - $51.98
52 WEEK CHANGE
-$0.88
MARKET CAP 
9.900 M
YIELD 
N/A
SHARES OUTSTANDING 
1.728 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.36
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$19,600
AVERAGE 30 VOLUME 
$54,408
Company detail
CEO:
Region: US
Website: vaccinex.com
Employees: 39
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop

Recent news